KNG1 and hereditary angioedema: We show that the effects of orally administered KVD900 on DXS‐stimulated PKa activity and HK cleavage observed in HAE subjects enrolled in the phase 2 trial were consistent with the observations of the pharmacodynamic effects of KVD900 in healthy volunteers.